12:36 PM EST, 12/03/2024 (MT Newswires) -- (Updates with the latest stock price movement in the headline and the first paragraph.)

TransMedics' ( TMDX ) shares were down more than 15% in recent Tuesday trading, a day after the company said it named Gerardo Hernandez as chief financial officer.

Hernandez was most recently vice president finance, head of corporate financial planning and analysis at Alnylam Pharmaceuticals (ALNY), TransMedics ( TMDX ) said.

Hernandez succeeds Stephen Gordon, who will remain a non-executive employee until March 31, 2025.

Gordon will then become a non-employee senior advisor to TransMedics ( TMDX ) focusing on national transplant stakeholder engagement until March 31, 2026, the company said.

TransMedics ( TMDX ) also said it now expects full-year 2024 revenue between $428 million and $432 million, which is a 77% to 79% increase compared with its previous year revenue.

Analysts polled by Factset expect $431.9 million.

Price: 72.03, Change: -13.11, Percent Change: -15.40